MapLight Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MPLT and other ETFs, options, and stocks.

About MPLT

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. 

CEO
Christopher A. Kroeger
CEOChristopher A. Kroeger
Employees
Employees
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
2018
Founded2018
Employees
Employees

MPLT Key Statistics

Market cap
848.02M
Market cap848.02M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
190.39K
Average volume190.39K
High today
$19.67
High today$19.67
Low today
$17.00
Low today$17.00
Open price
$17.17
Open price$17.17
Volume
343.86K
Volume343.86K
52 Week high
$21.55
52 Week high$21.55
52 Week low
$12.24
52 Week low$12.24

Stock Snapshot

The current MapLight Therapeutics(MPLT) stock price is $18.58, with a market capitalization of 848.02M.

As of 2026-01-23, MapLight Therapeutics(MPLT) stock has fluctuated between $17.00 and $19.67. The current price stands at $18.58, placing the stock +9.3% above today's low and -5.5% off the high.

The MapLight Therapeutics(MPLT)'s current trading volume is 343.86K, compared to an average daily volume of 190.39K.

In the last year, MapLight Therapeutics(MPLT) shares hit a 52-week high of $21.55 and a 52-week low of $12.24.

In the last year, MapLight Therapeutics(MPLT) shares hit a 52-week high of $21.55 and a 52-week low of $12.24.

People also own

Based on the portfolios of people who own MPLT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.